Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Cisplatin/Irinotecan Followed By Combination Carboplatin, Etoposide And Chest Radiotherapy In Limited Stage Small Cell Lung Cancer
NCT00072527Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2003
- Primary completion
- Jun 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132), irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Survival at 2 years. Started Nov 2003; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00072527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072527.